Cowen Reiterates Outperform on Ironwood Pharma (IRWD) Following IW-1973 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ironwood Pharma (IRWD) Reports Positive Impact from Praliciguat Phase IIa Study Data on Metabolic a& Cardiovascular Clinical Endpoints
June 25, 2018 5:54 AM EDTIronwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today presented additional data from an exploratory Phase IIa study of praliciguat (IW-1973) in patients with type 2 diabetes and hypertension during an oral session at the American Diabetes Associations (ADA) 78th Scientific Sessions in Orlando, Fla. Praliciguat is an oral, once-daily soluble guanylate cyclase (sGC) stimulator that... More
Ironwood Pharma (IRWD) Commences Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease
June 21, 2018 4:06 PM EDTIronwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the initiation of two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD). Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton... More
